Popular Articles

Two Types Of Urgency - Overactive Bladder - Urgency Is Not Just Urgency
UroToday.com - "Urgency" is the cornerstone of the diagnosis of overactive bladder (OAB) as well as a common complaint of patients with BPS/IC. What the term actually refers to when used by patients remains problematic and the subject of some controversy. The International Continence Society defines it as a "sudden compelling desire to void that is difficult to defer". The word sudden is designed to differentiate the sensation from the "urgency" that patients with BPS/IC complain of, but the distinction is quite vague in practice. Many believe that it is the reason for the urgency (fear of incontinence vs. pain) that should make the distinction.

RegeneRx Working With U.S. Military To Test Tí˛4 Against Exposure To Chemical Agents In The Eye
Regenerx Biopharmaceuticals, Inc. (NYSE Amex:RGN) (the "Company" or "RegeneRx") announced today that it is collaborating with the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) and Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University, to evaluate Tí˛4"s (RGN-259 eye drops) ability to prevent or reduce damage to the eye caused by exposure to chemical agents. The ability to prevent or reduce such damage is the focus of substantial efforts by both the military and homeland security. The project will consist of a series of research experiments over the next twelve months with Tí˛4, which is being commercially developed by RegeneRx and is in Phase II clinical trials.
News of the day
New Method For Breast Cancer Biomarker Discovery Developed By VBI Researchers
Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. The method has allowed the scientists to look at how the levels of proteins change in breast cancer cells when they are treated with hormones or cancer drugs like tamoxifen.
Diagnostics

AARP Responds To Health Reform Scare Tactics

AARP Executive Vice President John Rother issued the following statement in response to recent commentary by Betsy McCaughey in various media outlets on health care reform measures passed or currently being considered by Congress. "Betsy McCaughey"s recent commentary on health care reform column in various media outlets is rife with gross-and even cruel-distortions. "Ms. McCaughey has again launched her customary broadside attack against comparative effectiveness research. She describes this term as "code" for "limiting care based on a patient"s age." In fact the term for that is "age rating," a practice used by insurance companies to discriminate against older Americans against which AARP is vigorously fighting, and we look forward to her next column to help the cause. ""Comparative effectiveness research," on the other hand, is a technical term that just means giving doctors and patients the ability to compare different kinds of treatments to find out which one works best for which patient. "Some estimates say that only about half of all therapies that patients receive have been backed up by head-to-head comparisons with alternatives. While our country spends more than $2 trillion a year on health care, we spend less than 0.1 percent on evaluating how that care works compared to other options. "This research has been around (although sadly not enough) for decades, enjoying support from political leaders of both parties, doctors, patients, and consumer advocacy groups. "The main opponents of this research are those groups with a vested interest in a health care system that wastes billions of dollars each year on ineffective or unnecessary drugs, treatments or tests. Given Ms. McCaughey"s position as a Director of a medical device producer, I would hope that any potential conflict of interest has not influenced her commentary. "More concerning, Ms. McCaughey"s criticism misinterprets legislation that would actually help empower individuals and doctors to make their own choices on end-of-life care. "This measure would allow Medicare to pay doctors for taking the time to talk with individuals about difficult end-of-life care decisions. It would help provide people with better information on the positives and negatives-both physical and financial-that different treatments can mean for them and their families. "Facing a terminal disease or debilitating accident, some people will choose to take every possible life-saving measure in the hopes that treatment or even a cure will allow them more time with their families. Others will decide that additional treatment would impose too great a burden-emotional, physical and otherwise-on themselves and their families, declining extraordinary measures and instead choosing care to manage their discomfort. Either way, it should be their choice. "This measure would not only help people make the best decisions for themselves, but also better ensure that their wishes are followed. "To suggest otherwise is a gross, and even cruel, distortion-especially for any family that has been forced to make the difficult decisions on care for loved ones approaching the end of their lives. "AARP is committed to improving the quality, effectiveness, and affordability of health care for our 40 million members and their families. We will fight any measure that would prevent individuals and their doctors from making their own health care decisions. We will also fight the campaign of misinformation that vested interests are using to try to scare older Americans in order to protect the status quo. Profits should never be allowed to come before people in this debate." AARP


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):